SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01341743
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      The purpose of this study is to evaluate the efficacy and safety of generic entecavir
      monotherapy or in combination with adefovir for chronic hepatitis B patients with inadequate
      response to NUC therapy
    
Name: Entecavir
Description: patients will receive oral entecavir 1mg, daily for 104 weeks.
 Type: Drug
 Name: Entecavir, Adefovir
Description: patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
 Type: Drug
 Name: Entecavir, Adefovir
Description: patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
 Type: Drug
  
Primary Outcomes 
 Measure: proportion of subjects with hepatitis B virus (HBV)DNA<300copies/ml at week 104 Time: week 104
   
Secondary Outcomes 
 Measure: serum HBV DNA reduction from baseline at week 104 Time: week 104
 Measure: The proportion of subjects with ALT normalization at week 104 Time: week104
 Measure: The proportion of subjects with HBeAg loss and seroconversion at week 104 Time: week104
 Measure: The proportion of subject with HBsAg loss and seroconversion at week 104 Time: week104
 Measure: The proportion of subjects with mutations of rtN236T/A181V, rtL180M/rtM204V/rtT184/rtS202 and/or rtM250 at week 104 Time: week104
 
Purpose: Treatment
Allocation: Randomized
Parallel Assignment 
There is one SNP
SNPs
1 A181V 
The proportion of subjects with mutations of rtN236T/A181V, rtL180M/rtM204V/rtT184/rtS202 and/or rtM250 at week 104. --- A181V ---